Dr Lucas talks to ecancer at ESMO 2024 about data she presented from the phase 3 NADINA trial, looking at immunotherapy in resectable, macroscopic stage III melanoma.
The use of neoadjuvant ipilimumab plus nivolumab in resectable, macroscopic stage III melanoma resulted in improved distant metastasis-free survival and event free survival (EFS) as compared to adjuvant nivolumab.
This EFS-benefit was observed within stage IIIB- and IIIC melanoma.